Snøffelen
08.06.2018 kl 12:31 4118

Illuminati, FOLFIRINOX-studien omhandler pasienter med exocrine opprinnelse (PDAC), og ikke endocrine:

"In the adjuvant approach to pancreatic ductal adenocarcinoma (PDAC), I think that the data in favor of FOLFIRINOX over gemcitabine are practice-changing insofar as I have never seen a median survival in PDAC of this length,” Mark A. Lewis, MD, of Intermountain Healthcare, told Targeted Oncology"

PDAC betyr at opprinnelsen er i (pancreatic duct) dvs i epitelceller, eller "overflateceller".

De 55 mnd på FOLFIRINOX kan neppe forklares med endocrine opprinnelse.
Arkivert